Clinical Tumor Sequencing: Applications and Considerations for Targeted Sequencing using Anchored Multiplex PCR
Join us from 11am-12pm.
About This EventJoin us for a webinar by Patrick Hurban, Ph.D., Senior Director and Global Head, Translational Genomics.
Webinar abstract: Targeted sequencing of cancer genomes is a powerful tool for clinical development of targeted therapeutics, enabling comprehensive mutation profiling from low-input FFPE-preserved tumor samples. Anchored Multiplex PCR (AMP™) is a target enrichment chemistry for next-generation sequencing (NGS) that is well suited for sequencing of FFPE specimens, as the molecular barcoded adaptors utilized in AMP preserve library complexity of low-input, degraded samples. Unidirectional gene-specific primers permit open-ended capture of nucleic acid fragments for NGS-based identification of known and novel mutations, including SNVs/indels, copy number variants and gene fusions.
In this webinar, Dr. Hurban will review multiple applications of AMP-based NGS performed in a global CRO, discussing assay suitability and performance for multiple disease and mutation types.
Senior Director and Global Head, Translational Genomics
Patrick Hurban, Ph.D. is senior director and global head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes.
Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.
Following a Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill, he earned his Ph.D. in Human Genetics from the University of Utah in Salt Lake City before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University.